School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University , Clayton , Australia.
Chronobiol Int. 2019 Oct;36(10):1373-1383. doi: 10.1080/07420528.2019.1644652. Epub 2019 Aug 1.
Studies on circadian timing in depression have produced variable results, with some investigations suggesting phase advances and others phase delays. This variability may be attributable to differences in participant diagnosis, medication use, and methodology between studies. This study examined circadian timing in a sample of unmedicated women with and without unipolar major depressive disorder. Participants were aged 18-28 years, had no comorbid medical conditions, and were not taking medications. Eight women were experiencing a major depressive episode, nine had previously experienced an episode, and 31 were control participants with no history of mental illness. Following at least one week of actigraphic sleep monitoring, timing of salivary dim light melatonin onset (DLMO) was assessed in light of <1 lux. In currently depressed participants, melatonin onset occurred significantly earlier relative to sleep than in controls, with a large effect size. Earlier melatonin onset relative to sleep was also correlated with poorer mood for all participants. Our results indicate that during a unipolar major depressive episode, endogenous circadian phase is advanced relative to sleep time. This is consistent with the early-morning awakenings often seen in depression. Circadian misalignment may represent a precipitating or perpetuating factor that could be targeted for personalized treatment of major depression.
关于抑郁症昼夜节律的研究结果不一,一些研究表明存在相位提前,而另一些则表明存在相位延迟。这种变异性可能归因于研究之间参与者诊断、用药和方法的差异。本研究在未用药的女性中检查了昼夜节律计时,这些女性患有或未患有单相重性抑郁症。参与者年龄在 18-28 岁之间,没有合并的医疗条件,也没有服用药物。8 名女性正在经历重性抑郁发作,9 名女性以前经历过发作,31 名是没有精神疾病史的对照参与者。在进行至少一周的活动记录仪睡眠监测后,根据<1 勒克斯评估唾液褪黑素微光起始 (DLMO) 的时间。在目前抑郁的参与者中,与对照组相比,褪黑素的起始时间明显早于睡眠,且具有较大的效应量。对于所有参与者,褪黑素起始时间相对于睡眠的提前与情绪较差呈正相关。我们的研究结果表明,在单相重性抑郁发作期间,内源性昼夜节律相位相对于睡眠时间提前。这与抑郁症中常见的清晨觉醒一致。昼夜节律失调可能是一种促发或持续的因素,可作为单相重性抑郁症的个性化治疗靶点。